-Interim data from Phase 2 ReACT study of rindopepimut in recurrent GBM to be presented- -Additional presentations on rindopepimut compassionate use experience and EGFRvIII vaccine technology- HAMPTON, N.J., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from the rindopepimut program were published in the 2014 abstract supplement to the journal Neuro-Oncology and can be viewed online at http://neuro-oncology.oxfordjournals.org/.
- The first abstract is entitled "ReACT: A Phase 2 study of rindopepimut vaccine (CDX-110) plus bevacizumab in relapsed glioblastoma." Data included in this abstract were as of the time of submission (June 2014). An interim update containing more comprehensive, current data from the study will be presented by David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Dana Farber Cancer Center and Associate Professor of Medicine, Harvard Medical School in a platform presentation on Friday, November 14, 2014 from 3:35 to 3:45 pm ET.
- The second abstract is entitled "Vaccination against Epidermal Growth Factor Receptor variant III in glioblastoma: the rindopepimut compassionate use experience." Data from the rindopepimut compassionate use experience will be presented by Evangelia Razis, MD, PhD, Head, 3rd Oncology Unit Hygeia Hospital, Athens, Greece in a platform presentation on Friday, November 14, 2014 from 4:05 to 4:15 pm ET.
- Rindopepimut will also be discussed in a presentation by Michael Weller, MD, Professor, Department of Neurology, University Hospital Zurich, in a Sunrise Session on Vaccine Therapy on Sunday, November 16, 2014 from 7:00 to 8:00 am ET.
- Celldex will host a conference call and live webcast on Friday, November 14, 2014 at 5:00 pm ET to review the data presented at SNO. The conference call and presentation will be webcast live over the Internet and can be accessed by logging on to the Events Calendar under the "News & Events" section of the Celldex Therapeutics website at www.celldextherapeutics.com. The call can also be accessed by dialing (866) 743-9666 (within the United States) or (760) 298-5103 (outside the United States). The passcode is 28183516. A replay of the call will be available approximately two hours after the live call concludes through November 21, 2014. To access the replay, dial (855) 859-2056 (within the United States) or (404) 537-3406 (outside the United States). The passcode is 28183516. The webcast will also be archived on the Company's website.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Company Contact: Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 email@example.com Media Inquiries: Dan Budwick Pure Communications, Inc. (973) 271-6085 firstname.lastname@example.org